Pages

Friday, 10 January 2020

FDA-approved stomach cancer drug sends Blueprint Medicines’ stock up before resettling


FDA-approved stomach cancer drug sends Blueprint Medicines’ stock up before resettling



Shares were hovering around $82 as of press time.

No comments:

Post a Comment